Renk's $150 Million US Bet Aims to Unlock a Record Order Book
Published on 04/16/2026 at 15:02 | Redaktion boerse-global.de
Trading nearly 40% below its October peak, Renk Group's stock price tells a story of deep market skepticism. This stands in stark contrast to the German defense specialist's financials, which reveal a record order backlog of €6.68 billion—five times its annual revenue. The disconnect hinges on a single, critical challenge: converting those massive orders into reliable cash flow.
A primary bottleneck is geopolitical. The German government is currently withholding export licenses for RK-325 gear systems destined for Israeli Merkava and Namer vehicles. This blockade puts €80 to €100 million in projected 2026 revenue at risk. For a company heavily reliant on a few major programs like the Leopard 2 and Puma infantry fighting vehicle, such delays directly undermine financial predictability.
The American Solution
CEO Alexander Sagel's strategic response is a decisive shift westward. The affected production line is slated for relocation from Germany to Renk's existing facility in Muskegon, Michigan. This move is designed to circumvent German export restrictions by fulfilling orders through the US Foreign Military Sales program. It is far from a temporary fix; Renk plans to invest $150 million in its US sites by 2030.
The expansion aims to dramatically scale output. Annual production capacity, recently between 200 and 300 gear units, is targeted to reach 800 by the end of 2026. This US push is already gaining traction, with Renk America securing a US Army contract worth up to $75.5 million in January for technical system support on the Bradley fighting vehicle.
Should investors sell immediately? Or is it worth buying Renk?
Strong Fundamentals Meet Technical Weakness
Renk's underlying performance remains robust. Revenue grew by 19.8% to €1.37 billion in 2025. For the current year, management targets sales exceeding €1.5 billion and an adjusted EBIT between €255 million and €285 million. Despite this, the share price languishes around €53, below key moving averages. The 50-day average sits at €55.17 and the 200-day at €61.26.
The stock's Relative Strength Index of 33.7 indicates technically oversold conditions, yet sustained buying interest has been absent. This weakness has attracted short-sellers, with hedge funds like AQR increasing their net short positions to 2.30%. In a contrasting signal, CFO Anja Mänz-Siebje recently purchased shares personally following the price decline.
Analyst opinions reflect the market's divided view on Renk's execution capability. J.P. Morgan's David Perry maintains a 'Buy' rating with a €75 price target, citing the confirmed backlog and revenue guidance. Berenberg sees fair value at €76, while mwb research considers the stock fairly valued at its current €53 level.
Renk at a turning point? This analysis reveals what investors need to know now.
The Capacity Ceiling
Management itself has tempered expectations, acknowledging that scaling production is a multi-year endeavor. The company has indicated that revenues significantly above €2 billion are not realistic before 2028. While Germany's bolstered 2026 defense budget—comprising a €82.7 billion core budget and a €25.5 billion special fund—provides structural tailwinds, it does not instantly accelerate Renk's supply chain.
All eyes are now on the company's upcoming communications. The Q1 pre-close call on April 22, followed by detailed quarterly results on May 6, will be critical. Investors will scrutinize whether the US relocation can compensate for the lost Israeli revenue swiftly enough and if delayed orders are transitioning into recognized sales as planned. Demonstrating tangible progress on converting its monumental backlog into earnings is the key to reversing the persistent downward pressure on the stock.
Ad
Renk Stock: New Analysis - 16 April
Fresh Renk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
